Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/25744
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorGOIS, Pedro Henrique Franca-
dc.contributor.authorMARTINES, Monique Silva-
dc.contributor.authorFERREIRA, Daniela-
dc.contributor.authorVOLPINI, Rildo-
dc.contributor.authorCANALE, Daniele-
dc.contributor.authorMALAQUE, Ceila-
dc.contributor.authorCRAJOINAS, Renato-
dc.contributor.authorGIRARDI, Adriana Castello Costa-
dc.contributor.authorSHIMIZU, Maria Heloisa Massola-
dc.contributor.authorSEGURO, Antonio Carlos-
dc.date.accessioned2018-03-06T15:21:12Z-
dc.date.available2018-03-06T15:21:12Z-
dc.date.issued2017-
dc.identifier.citationPLOS NEGLECTED TROPICAL DISEASES, v.11, n.11, article ID e0006024, 15p, 2017-
dc.identifier.issn1935-2735-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/25744-
dc.description.abstractSnakebites have been recognized as a neglected public health problem in several tropical and subtropical countries. Bothrops snakebites frequently complicate with acute kidney injury (AKI) with relevant morbidity and mortality. To date, the only treatment available for Bothrops envenomation is the intravenous administration of antivenom despite its several limitations. Therefore, the study of novel therapies in Bothrops envenomation is compelling. The aim of this study was to evaluate the protective effect of Allopurinol (Allo) in an experimental model of Bothrops jararaca venom (BJ)-associated AKI. Five groups of Wistar rats were studied: Sham, Allo, BJ, BJ+Allo, BJ+ipAllo. BJ (0.25 mg/kg) was intravenously injected during 40'. Saline at same dose and infusion rate was administered to Sham and Allo groups. Allo and BJ+Allo groups received Allo (300 mg/L) in the drinking water 7 days prior to Saline or BJ infusion respectively. BJ+ipAllo rats received intraperitoneal Allo (25 mg/Kg) 40' after BJ infusion. BJ rats showed markedly reduced glomerular filtration rate (GFR, inulin clearance) associated with intense renal vasoconstriction, hemolysis, hemoglobinuria, reduced glutathione and increased systemic and renal markers of nitro-oxidative stress (Nitrotyrosine). Allo ameliorated GFR, renal blood flow (RBF), renal vascular resistance and arterial lactate levels. In addition, Allo was associated with increased serum glutathione as well as reduced levels of plasma and renal Nitrotyrosine. Our data show that Allo attenuated BJ-associated AKI, reduced oxidative stress, improved renal hemodynamics and organ perfusion. It might represent a novel adjuvant approach for Bothrops envenomation, a new use for an old and widely available drug.-
dc.description.sponsorshipNational Council for Scientific and Technological Development (CNPq) [306148/2013-7]-
dc.description.sponsorshipSao Paulo Research Foundation (FAPESP) [2015/11933-3]-
dc.language.isoeng-
dc.publisherPUBLIC LIBRARY SCIENCE-
dc.relation.ispartofPlos Neglected Tropical Diseases-
dc.rightsopenAccess-
dc.subject.otheroxidative stress-
dc.subject.otheruric-acid-
dc.subject.othersnake-venom-
dc.subject.otherexperimental-model-
dc.subject.otherhemorrhagic-shock-
dc.subject.otherrenal-failure-
dc.subject.otherbites-
dc.subject.otherhyperuricemia-
dc.subject.otherpretreatment-
dc.subject.otherreperfusion-
dc.titleAllopurinol attenuates acute kidney injury following Bothrops jararaca envenomation-
dc.typearticle-
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCE-
dc.identifier.doi10.1371/journal.pntd.0006024-
dc.identifier.pmid29155815-
dc.subject.wosInfectious Diseases-
dc.subject.wosParasitology-
dc.subject.wosTropical Medicine-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalMARTINES, Monique Silva:Univ Sao Paulo, Sch Med, Nephrol Dept, Lab Med Res LIM12, Sao Paulo, Brazil-
hcfmusp.author.externalFERREIRA, Daniela:Univ Sao Paulo, Sch Med, Nephrol Dept, Lab Med Res LIM12, Sao Paulo, Brazil-
hcfmusp.author.externalMALAQUE, Ceila:Vital Brazil Hosp, Butantan Inst, Sao Paulo, Brazil-
hcfmusp.description.articlenumbere0006024-
hcfmusp.description.issue11-
hcfmusp.description.volume11-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-85036662824-
hcfmusp.origem.idWOS:000416832800017-
hcfmusp.publisher.citySAN FRANCISCO-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAlape-Giron A, 2008, J PROTEOME RES, V7, P3556, DOI 10.1021/pr800332p-
hcfmusp.relation.referenceALLAN G, 1986, BRIT J PHARMACOL, V89, P149, DOI 10.1111/j.1476-5381.1986.tb11130.x-
hcfmusp.relation.referenceAMARAL CFS, 1985, TOXICON, V23, P877, DOI 10.1016/0041-0101(85)90379-4-
hcfmusp.relation.referenceBadr KF, 2005, ANTIOXID REDOX SIGN, V7, P236, DOI 10.1089/ars.2005.7.236-
hcfmusp.relation.referenceBoer-Lima PA, 1999, AM J TROP MED HYG, V61, P698, DOI 10.4269/ajtmh.1999.61.698-
hcfmusp.relation.referenceBrown NI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001670-
hcfmusp.relation.referenceBURDMANN EA, 1993, AM J TROP MED HYG, V48, P82, DOI 10.4269/ajtmh.1993.48.82-
hcfmusp.relation.referenceCalvete JJ, 2011, J PROTEOMICS, V74, P510, DOI 10.1016/j.jprot.2011.01.003-
hcfmusp.relation.referenceCardoso J. L. C., 2009, ANIMAIS PECONHENTOS-
hcfmusp.relation.referenceCASTELLI P, 1995, J CARDIOVASC PHARM, V25, P119, DOI 10.1097/00005344-199501000-00019-
hcfmusp.relation.referenceCHAVES F, 1995, TOXICON, V33, P31, DOI 10.1016/0041-0101(94)00135-U-
hcfmusp.relation.referenceChippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515-
hcfmusp.relation.referenceCUNNINGHAM SK, 1978, EUR SURG RES, V10, P305, DOI 10.1159/000128020-
hcfmusp.relation.referencede Castroa I, 2004, TOXICON, V43, P833, DOI 10.1016/j.toxicon.2004.03.015-
hcfmusp.relation.referenceDoley R, 2009, CELL MOL LIFE SCI, V66, P2851, DOI 10.1007/s00018-009-0050-2-
hcfmusp.relation.referenceErol T, 2013, INT J CARDIOL, V167, P1396, DOI 10.1016/j.ijcard.2012.04.068-
hcfmusp.relation.referenceFeig DI, 2006, J AM SOC NEPHROL, V17, pS69, DOI 10.1681/ASN.2005121331-
hcfmusp.relation.referenceGois PHF, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008652.pub3-
hcfmusp.relation.referenceGasparovic AC, 2017, BRIT J PHARMACOL, V174, P1771, DOI 10.1111/bph.13673-
hcfmusp.relation.referenceGois PHF, 2016, FREE RADIC BIOL MED, P101-
hcfmusp.relation.referenceGoncalves-Machado L, 2016, J PROTEOMICS, V135, P73, DOI 10.1016/j.jprot.2015.04.029-
hcfmusp.relation.referenceGuan WP, 2003, J CARDIOVASC PHARM, V41, P699, DOI 10.1097/00005344-200305000-00005-
hcfmusp.relation.referenceGutierrez JM, 2006, PLOS MED, V3, P727, DOI 10.1371/journal.pmed.0030150-
hcfmusp.relation.referenceGutierrez Jose Maria, 2011, Inflammation & Allergy Drug Targets, V10, P369-
hcfmusp.relation.referenceHarrison RA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000569-
hcfmusp.relation.referenceJohnson RJ, 2013, NEPHROL DIAL TRANSPL, V28, P2221, DOI 10.1093/ndt/gft029-
hcfmusp.relation.referenceKasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218-
hcfmusp.relation.referenceKeel CE, 2013, UROLOGY, V81, DOI 10.1016/j.urology.2012.08.016-
hcfmusp.relation.referenceKhosla UM, 2005, KIDNEY INT, V67, P1739, DOI 10.1111/j.1523-1755.2005.00273.x-
hcfmusp.relation.referenceKossmann S, 2014, J BIOL CHEM, V289, P27540, DOI 10.1074/jbc.M114.604231-
hcfmusp.relation.referenceLegrand M, 2008, MOL MED, V14, P502, DOI 10.2119/2008-00006.Legrand-
hcfmusp.relation.referenceGutierrez JM, 2010, J PROTEOME RES, V9, P564, DOI 10.1021/pr9009518-
hcfmusp.relation.referenceGutierrez JM, 2009, TOXICON, V54, P976, DOI 10.1016/j.toxicon.2009.01.039-
hcfmusp.relation.referenceMartines MS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086828-
hcfmusp.relation.referenceMazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839-
hcfmusp.relation.referenceMEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431-
hcfmusp.relation.referenceMoore KP, 1998, J BIOL CHEM, V273, P31731, DOI 10.1074/jbc.273.48.31731-
hcfmusp.relation.referenceNunez V, 2009, J PROTEOMICS, V73, P57, DOI 10.1016/j.jprot.2009.07.013-
hcfmusp.relation.referenceOtero-Patino R, 2009, TOXICON, V54, P998, DOI 10.1016/j.toxicon.2009.07.001-
hcfmusp.relation.referencePacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6-
hcfmusp.relation.referenceRibeiro LA, REV I MED TROP SAO P, V32, P436-
hcfmusp.relation.referenceRodrigues RS, 2009, BIOCHIMIE, V91, P490, DOI 10.1016/j.biochi.2008.12.004-
hcfmusp.relation.referenceSanchez-Lozada LG, 2008, AM J PHYSIOL-RENAL, V295, pF1134, DOI 10.1152/ajprenal.00104.2008-
hcfmusp.relation.referenceSanthosh MS, 2013, J THROMB THROMBOLYS, V36, P424, DOI 10.1007/s11239-013-0888-x-
hcfmusp.relation.referenceSantos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491-
hcfmusp.relation.referenceSapalidis Konstantinos, 2013, J Emerg Trauma Shock, V6, P203, DOI 10.4103/0974-2700.115346-
hcfmusp.relation.referenceSautin YY, 2007, AM J PHYSIOL-CELL PH, V293, pC584, DOI 10.1152/ajpcell.00600.2006-
hcfmusp.relation.referenceSEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4-
hcfmusp.relation.referenceSgrignolli LR, 2011, NEPHRON CLIN PRACT, V119, pC131, DOI 10.1159/000324228-
hcfmusp.relation.referenceSharma V, 2009, BRIT J PHARMACOL, V157, P907, DOI 10.1111/j.1476-5381.2009.00267.x-
hcfmusp.relation.referenceStrapazzon JD, 2015, J APPL BIOMED, V13, P161, DOI 10.1016/j.jab.2014.11.002-
hcfmusp.relation.referenceSunitha K, 2015, TOXICON, V98, P89, DOI 10.1016/j.toxicon.2015.02.014-
hcfmusp.relation.referenceTAN NH, 1991, COMP BIOCHEM PHYS B, V100, P361, DOI 10.1016/0305-0491(91)90387-S-
hcfmusp.relation.referenceTanabe K, 2014, J CARDIOL, V64, P86, DOI 10.1016/j.jjcc.2013.11.017-
hcfmusp.relation.referenceWalker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143-
hcfmusp.relation.referenceWayenberg JL, 2009, FREE RADICAL BIO MED, V47, P975, DOI 10.1016/j.freeradbiomed.2009.07.003-
hcfmusp.relation.referenceWeston RE, 1943, AM J PHYSIOL, V138, P0450-
hcfmusp.relation.referenceWilliams DJ, 2011, J PROTEOMICS, V74, P1735, DOI 10.1016/j.jprot.2011.05.027-
hcfmusp.relation.referenceZengin S, 2014, EMERG MED J, V31, P48, DOI 10.1136/emermed-2012-202013-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus10-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/12
LIM/12 - Laboratório de Pesquisa Básica em Doenças Renais

Artigos e Materiais de Revistas Científicas - LIM/13
LIM/13 - Laboratório de Genética e Cardiologia Molecular

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Artigos e Materiais de Revistas Científicas - ODS/06
ODS/06 - Água potável e saneamento


Files in This Item:
File Description SizeFormat 
art_GOIS_Allopurinol_attenuates_acute_kidney_injury_following_Bothrops_jararaca_2017.PDFpublishedVersion (English)10.6 MBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.